29.6.2022 12:11:23 CEST | Monsenso |
Selskabsmeddelelse
Selskabsmeddelelse nr. 06-2022
København, 29. juni 2022
Bestyrelsen i Monsenso A/S offentliggør hermed beslutningen om at udstede warrants til medarbejdere, herunder direktion, der er i uopsagt stilling og som var ansat 1. januar 2022.
Warrants modnes over 36 måneder fra 1.maj 2022 til 30. april 2025, men kun såfremt modtageren stadig er ansat i selskabet. Ikke udnyttede warrants bortfalder 31.august 2029. Der er tildelt DKK 801.900 warrants, der giver ret til tegning af nominelt DKK 80.190 aktier i selskabet.
Bestyrelsen har fastsat udnyttelseskursen til DKK 0,66 pr warrant i overensstemmelse med § 5.3 i selskabets vedtægter.
Warrantmodtageren skal ikke betale vederlag for at tegne warrants. De modnede warrants kan udnyttes 2 gange om året efter offentliggørelse af selskabets års- og halvårsrapport i et udnyttelsesvindue på p.t. 2 uger.
Monsenso’s aktiekapital udgør nominelt DKK 2.322.313,30 fordelt på 23.223.133 styk aktier a DKK 0,10.
Eventuelle henvendelser vedrørende denne meddelelse bedes rettet til:
Monsenso
Chairman of the boardPeter Mørch EriksenTel. +45 29 00 35E-mail: pme@bioporto.com
CEO Thomas LethenborgTlf. +45 21 29 88 27E-mail: lethenborg@monsenso.com
Certified Adviser:
Norden CEF A/SJohn NordenTlf. +45 20 72 02 00E-mail: jn@nordencef.dk
Om Monsenso
Monsenso er en innovativ virksomhed, som tilbyder en digital sundhedsløsning for mentale lidelser. Vores mission er at bidrage til bedre mental sundhed til flere personer og lavere omkostninger. Vores løsning bidrager til optimering af behandlingen af psykiske lidelser og giver et detaljeret overblik over patienters mentale sundhed via indsamling af data om mental tilstand, adhærens og adfærd. Løsningen forbinder patienter, omsorgspersoner og behandlere for at muliggøre en personligt tilpasset behandling, distancebehandling samt tidlig opsporing og intervention. Baseret på vedvarende forskning og udvikling er vores team opsat på at udvikle løsninger, der passer ind i brugernes liv, øger patienters livskvalitet og forbedrer effekten af behandlingen. Få mere at vide på www.monsenso.com
Vedhæftninger
Download selskabsmeddelelse.pdf
29.6.2022 12:11:23 CEST | Monsenso |
Company Announcement
Company announcement no. 06-2022
Copenhagen, 2022.06.29
The Board of Directors of Monsenso A/S hereby announces the decision to issue warrants for employees and management, who are in a non-terminated position and who were employed on 1 January 2022.
Vesting period for the warrants is 36 months from 1 May 2022 to 30 April 2025, but only if the recipient is still employed by the company. Unexercised warrants expire on 31 August 2029. DKK 801,900 warrants have been granted, giving the right to subscribe for a nominal DKK 80,190 shares in the company.
The Board of Directors has set the exercise price at DKK 0.66 per warrant, in accordance with § 5.3 of the company’s articles of association.
The warrant holder shall not pay any compensation for the granting of the warrants. The vested warrants can be exercised twice a year after publication of the company’s annual and half-yearly report in an exercise window of p.t. 2 weeks.
Monsenso’s share capital amounts to a nominal value of DKK 2,322,313.30 divided into 23,223,133 shares of DKK 0.10.
Any inquiries regarding this notice should be directed to:
Monsenso
Chairman of the boardPeter Mørch EriksenTel. +45 29 00 35E-mail: pme@bioporto.com
CEO Thomas LethenborgTlf. +45 21 29 88 27E-mail: lethenborg@monsenso.com
Certified Adviser:
Norden CEF A/SJohn NordenTlf. +45 20 72 02 00E-mail: jn@nordencef.dk
About Monsenso
Monsenso is an innovative technology company offering a digital health solution for mental health and behavioral disorders. Our mission is to help provide better mental health to more people at lower costs. Our solution helps optimise the treatment of mental disorders and gives a detailed overview of an individual’s mental health through the collection of outcome, adherence and behavioural data. It connects individuals, carers and health care providers to enable personalised treatment, remote care and early intervention. Based on continuous research and development, our team is committed to developing solutions that fit seamlessly into the lives of individuals, increase their quality of life and improve the efficacy of mental health treatment. To learn more visit www.monsenso.com
Attachments
Download announcement as PDF.pdf
